Alamar CEO restructures stake, gets new equity grants
Alamar Biosciences CEO Yuling Luo reported a series of equity restructurings and awards around the company’s initial public offering.
Rhea-AI Filing Summary
Alamar Biosciences CEO Yuling Luo reported a series of equity restructurings and awards around the company’s initial public offering. Several classes of preferred and Class A shares automatically converted into Class B Common Stock and were then reclassified into Common Stock immediately before the IPO, with no cash changing hands.
The filing also shows a grant of 76,509 restricted stock units that vest monthly, and a new stock option for 341,191 shares of Common Stock at an exercise price of $17.00 per share, vesting over four years. Many option entries reflect technical reclassifications between Class B Common Stock and Common Stock rather than market trades.
Positive
- None.
Negative
- None.
Insider Trade Summary
3,491,700 shares exercised/converted
Exercise
29 txns
Insider
Luo Yuling
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Class A Common Stock | 1,020,742 | $0.00 | $0.00 |
| Conversion | Founders Preferred Stock | 366,004 | $0.00 | $0.00 |
| Conversion | Series A-1 Preferred Stock | 880,802 | $0.00 | $0.00 |
| Conversion | Class A Common Stock | 1,224,152 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 266,311 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 266,311 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 25,310 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 25,310 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 23,986 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 23,986 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 20,023 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 20,023 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 27,700 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 27,700 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 1,033,912 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 1,033,912 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 37,086 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 37,086 | $0.00 | $0.00 |
| Other | Stock Option (Right to Buy) | 42,334 | $0.00 | $0.00 |
| Other | Stock Option ((Right to Buy) | 42,334 | $0.00 | $0.00 |
| Conversion | Class B Common Stock | 1,386,746 | $0.00 | $0.00 |
| Conversion | Class B Common Stock | 364,268 | $0.00 | $0.00 |
| Other | Class B Common Stock | 1,864,065 | $0.00 | $0.00 |
| Other | Common Stock | 1,864,065 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 76,509 | $0.00 | $0.00 |
| Conversion | Class B Common Stock | 1,224,152 | $0.00 | $0.00 |
| Other | Class B Common Stock | 1,224,152 | $0.00 | $0.00 |
| Other | Common Stock | 1,224,152 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 341,191 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 1,775,519 contracts (Direct);
Class A Common Stock — 0 contracts (Direct);
Founders Preferred Stock — 0 contracts (Direct);
Series A-1 Preferred Stock — 0 contracts (Direct);
Class A Common Stock — 0 contracts (Indirect, By Spouse);
Stock Option ((Right to Buy) — 42,334 contracts (Direct);
Class B Common Stock — 0 shares (Direct);
Common Stock — 1,940,574 shares (Direct);
Class B Common Stock — 0 shares (Indirect, By Spouse);
Common Stock — 1,224,152 shares (Indirect, By Spouse)
Footnotes (11)
- F1. The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO").
- F2. The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO.
- F3. Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
- F4. Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
- F5. Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
- F6. Fully vested.
- F7. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2023, subject to the reporting person's continuous service as of each such vesting date.
- F8. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2024, subject to the reporting person's continuous service as of each such vesting date.
- F9. The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
- F10. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.
- F11. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
Key Figures
RSU grant: 76,509 shares
New option grant: 341,191 shares at $17.00
Exercise/Conversion volume: 3,491,700 shares
+4 more
7 metrics
RSU grant
76,509 shares
Restricted stock units vesting monthly from grant date
New option grant
341,191 shares at $17.00
Stock option exercise price per share, expires on 2036-04-15
Exercise/Conversion volume
3,491,700 shares
Total derivative conversion/exercise shares in this filing
Restructuring volume
9,129,758 shares
Shares affected by J-code restructuring transactions
Preferred conversion ratio
1:1
Class A and Founders Preferred into Class B Common Stock
Series A-1 conversion ratio
1:2.418
Series A-1 Preferred into Class B Common Stock
Class B to Common
1:1
Each Class B Common Stock reclassified into one Common share
Key Terms
restricted stock units ("RSUs"), Class B Common Stock, Founders Preferred Stock, Series A-1 Preferred Stock, +2 more
6 terms
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Class B Common Stock financial
"Each share of Class B Common Stock was reclassified into one share of Common Stock"
A class B common stock is one of multiple types of a company’s ordinary shares that carries specific rights—often different voting power or dividend priority—compared with other classes. For investors it matters because those differences affect how much influence you have over company decisions, the income you might receive, and how freely the shares trade; think of it like owning a car with different keys: some keys let you start the engine and open the trunk, others only unlock the door.
Founders Preferred Stock financial
"The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock"
Series A-1 Preferred Stock financial
"The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis"
Series A-1 preferred stock is a specific class of company shares created in an early financing round that typically gives its holders priority over common shareholders for dividends and money if the company is sold or liquidates. Think of it as a special ticket with upfront privileges — often convertible into ordinary shares and sometimes carrying voting or protective rights — so investors use it to reduce risk and preserve control compared with ordinary stock.
initial public offering financial
"immediately prior to the completion of the initial public offering of the Issuer's Common Stock"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... the option vest in equal monthly installments over 48 months"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Alamar Biosciences (ALMR) report for CEO Yuling Luo?
Yuling Luo reported mainly equity restructurings and grants. The filing shows conversions of preferred and Class A shares into Class B, then into Common Stock, plus new RSU and stock option awards, with no open-market share purchases or sales disclosed.
What new equity awards did Alamar Biosciences grant to its CEO?
The CEO received 76,509 restricted stock units and a large option grant. The RSUs vest monthly, while a stock option for 341,191 Common shares at $17.00 per share vests over four years, tying compensation to future stock performance.
What do the restructuring (J-code) transactions at Alamar Biosciences represent?
The J-code entries reflect equity restructurings, not cash trades. They record reclassifications among Class A, Class B, preferred stock, and options into Common Stock in connection with the IPO and option repricings between different underlying share classes.
How do the new RSUs for Alamar Biosciences’ CEO vest over time?
The 76,509 RSUs vest in monthly installments. Vesting continues from the grant date as long as the CEO maintains continuous service, gradually delivering Common Stock rather than in one lump-sum release.
AI-generated analysis. How Rhea-AI works. Not financial advice.
